Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Gender differences in pharmacokinetics of maintenance dosed buprenorphine.

Moody DE, Fang WB, Morrison J, McCance-Katz E.

Drug Alcohol Depend. 2011 Nov 1;118(2-3):479-83. doi: 10.1016/j.drugalcdep.2011.03.024. Epub 2011 Apr 23.

2.

Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy.

Luo X, Trevejo J, van Heeswijk RP, Smith F, Garg V.

Antimicrob Agents Chemother. 2012 Jul;56(7):3641-7. doi: 10.1128/AAC.00077-12. Epub 2012 May 7.

3.

Urine naloxone concentration at different phases of buprenorphine maintenance treatment.

Heikman P, Häkkinen M, Gergov M, Ojanperä I.

Drug Test Anal. 2014 Mar;6(3):220-5. doi: 10.1002/dta.1464. Epub 2013 Mar 19.

PMID:
23512803
4.

Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.

Elkader A, Sproule B.

Clin Pharmacokinet. 2005;44(7):661-80. Review.

PMID:
15966752
5.

Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioid-dependent individuals.

Masson CL, Rainey PM, Moody DE, McCance-Katz EF.

Am J Addict. 2014 Jan-Feb;23(1):34-40. doi: 10.1111/j.1521-0391.2013.12052.x. Epub 2013 Jun 10.

6.

Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans.

Huestis MA, Cone EJ, Pirnay SO, Umbricht A, Preston KL.

Drug Alcohol Depend. 2013 Aug 1;131(3):258-62. doi: 10.1016/j.drugalcdep.2012.11.014. Epub 2012 Dec 14.

7.

Dexamethasone hepatic induction in rats subsequently treated with high dose buprenorphine does not lead to respiratory depression.

Hreiche R, Mégarbane B, Pirnay S, Borron SW, Monier C, Risède P, Milan N, Descatoire V, Pessayre D, Baud FJ.

Toxicol Appl Pharmacol. 2006 Dec 15;217(3):352-62. Epub 2006 Sep 30.

PMID:
17084876
8.

Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials.

Ciraulo DA, Hitzemann RJ, Somoza E, Knapp CM, Rotrosen J, Sarid-Segal O, Ciraulo AM, Greenblatt DJ, Chiang CN.

J Clin Pharmacol. 2006 Feb;46(2):179-92.

PMID:
16432270
9.
10.

Buprenorphine-cannabis interaction in patients undergoing opioid maintenance therapy.

Vierke C, Marxen B, Boettcher M, Hiemke C, Havemann-Reinecke U.

Eur Arch Psychiatry Clin Neurosci. 2020 Jan 6. doi: 10.1007/s00406-019-01091-0. [Epub ahead of print]

PMID:
31907614
11.

Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects.

Hagelberg NM, Fihlman M, Hemmilä T, Backman JT, Laitila J, Neuvonen PJ, Laine K, Olkkola KT, Saari TI.

Pharmacol Res Perspect. 2016 Nov 3;4(6):e00271. doi: 10.1002/prp2.271. eCollection 2016 Dec.

12.

LC-MS-MS analysis of buprenorphine and norbuprenorphine in whole blood from suspected drug users.

Seldén T, Roman M, Druid H, Kronstrand R.

Forensic Sci Int. 2011 Jun 15;209(1-3):113-9. doi: 10.1016/j.forsciint.2011.01.011. Epub 2011 Feb 8.

PMID:
21306845
13.

Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment.

Douglas Bruce R, Moody DE, Chodkowski D, Andrews L, Fang WB, Morrison J, Parsons TL, Friedland GH.

Am J Drug Alcohol Abuse. 2013 Mar;39(2):80-5. doi: 10.3109/00952990.2013.764885.

PMID:
23421567
14.

Estimated dose exposure of the neonate to buprenorphine and its metabolite norbuprenorphine via breastmilk during maternal buprenorphine substitution treatment.

Ilett KF, Hackett LP, Gower S, Doherty DA, Hamilton D, Bartu AE.

Breastfeed Med. 2012 Aug;7:269-74. doi: 10.1089/bfm.2011.0096. Epub 2011 Oct 19.

PMID:
22011128
16.

Pharmacokinetics of buprenorphine after intravenous administration in the mouse.

Yu S, Zhang X, Sun Y, Peng Y, Johnson J, Mandrell T, Shukla AJ, Laizure SC.

J Am Assoc Lab Anim Sci. 2006 May;45(3):12-6.

PMID:
16642964
17.

Opioid-induced constipation: rationale for the role of norbuprenorphine in buprenorphine-treated individuals.

Webster LR, Camilleri M, Finn A.

Subst Abuse Rehabil. 2016 Jun 14;7:81-6. doi: 10.2147/SAR.S100998. eCollection 2016. Review.

18.

Pharmaceutical and pharmacokinetic characterization of a novel sublingual buprenorphine/naloxone tablet formulation in healthy volunteers.

Fischer A, Jönsson M, Hjelmström P.

Drug Dev Ind Pharm. 2015 Jan;41(1):79-84. doi: 10.3109/03639045.2013.846365. Epub 2013 Oct 7.

19.

Incorporation of drugs for the treatment of substance abuse into pigmented and nonpigmented hair.

Wilkins DG, Valdez AS, Nagasawa PR, Gygi SP, Rollins DE.

J Pharm Sci. 1998 Apr;87(4):435-40.

PMID:
9548895
20.

Relative bioavailability of different buprenorphine formulations under chronic dosing conditions.

Strain EC, Moody DE, Stoller KB, Walsh SL, Bigelow GE.

Drug Alcohol Depend. 2004 Apr 9;74(1):37-43.

PMID:
15072805

Supplemental Content

Support Center